

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/35963 A1

- (51) International Patent Classification⁷: **A61K 31/55** [US/US]; 2821 Donnybrook Drive, Burleson, TX 76028 (US).
- (21) International Application Number: **PCT/US00/29436**
- (22) International Filing Date: 26 October 2000 (26.10.2000)
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/166,194 18 November 1999 (18.11.1999) **US**
- (71) Applicant (for all designated States except US): **ALCON UNIVERSAL LTD. [CH/CH]; P.O. BOX 62, Bosch 60, CH-6331 Hünenberg (CH).**
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **YANNI, John, M.**
- (74) Agents: **YEAGER, Sally, S. et al.; R & D Counsel, Mail Code Q-148, 6201 South Freeway, Fort Worth, TX 76134 (US).**
- (81) Designated States (national): **AU, BR, CA, CN, MX, PL, TR, US, ZA.**
- (84) Designated States (regional): **European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).**
- Published:**
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/35963 A1

(54) Title: **USE OF H₁ ANTAGONIST AND A SAFE STEROID TO TREAT EYE CONDITIONS**

(57) Abstract: **Compositions and methods for treating VKC, GPC, and AKC with H₁ antagonists and ocularly safe steroids are disclosed.**

USE OF AN H₁ ANTAGONIST AND A SAFE STEROID TO TREAT EYE CONDITIONS

5 The present invention is directed to the use of an H₁ antagonist in combination with an ocularly safe steroid to treat ocular conditions, specifically vernal keratoconjunctivitis (VKC), giant papillary conjunctivitis (GPC), and atopic keratoconjunctivitis (AKC).

10 Background of the Invention

 Vernal keratoconjunctivitis (VKC), giant papillary conjunctivitis (GPC), and atopic keratoconjunctivitis (AKC) have historically been treated with a regimen of oral or topical antihistamines and/or oral or topical steroids with varying degrees of
15 success (when used individually). Systemic treatment typically requires higher concentrations of the drug compound to be administered to afford an effective concentration to reach the necessary treatment site. Antihistamine compounds are known to have central nervous system (CNS) activity, which manifests itself in drowsiness and may have anticholinergic activity which manifests itself in the drying
20 of mucus membranes. Steroid therapy also has significant systemic side effects, including the elevation of intraocular pressure (IOP). Topical ocular use of steroids can also cause a rise in IOP and induce cataract formation.

 Topical ocular combination therapy is known. For example, U.S. Patent No.
25 5,192,780 (York, et al) discloses the use of an antihistamine and an antiallergic for treating ophthalmic allergic responses. U.S. Patent No. 5,149,694 (Cagle, et al.) discloses compositions of tobramycin and dexamethasone for the control of infection and inflammatory response.

30 The use of an H₁ antagonist in combination with a safe steroid for treating VKC, GPC, and AKC is not known.

Summary of the Invention

The present invention is directed to compositions of combinations of H₁ antagonists and safe steroids to treat VKC, GPC, and AKC. Methods for the use of the compositions in mammals are also contemplated.

Description of Preferred Embodiments

The current invention comprises compositions of H₁ antagonists for treating the itching, redness, and edema associated with VKC, GPC, and AKC. The compositions also include a safe steroid, as used herein the term "safe steroid" means a steroid which treats eosinophil and neutrophil associated inflammation, reduces papillae formation, and which is effective in treating inflammation without causing a clinically significant elevation in IOP.

The H₁ antagonists which are useful according to the present invention include all efficacious compounds, including, but not limited to: emedastine, levocabastine, mequitazine, chlorpheniramine, brompheniramine, astemizole, cetirizine, terfenadine, rocastine, loratadine, 5-[2-[4-bis(4-fluorophenyl)hydroxymethyl-1-piperidinyl]ethyl]-3-methyl]-2-oxazolidinone ethanedioate) pyrilamine, clemastine, azelastine, ketotifen, olopatadine, and mapinastine.

Safe steroids which can be used herein include any glucocorticoid which meets the safe steroid definition, including but not limited to, fluoromethalone, rimexolone, loteprednol, dexamethasone beloxil and its analogues described in U.S. Patent Nos. 5,223,493 and 5,420,120.

The H₁ antagonists and safe steroids (compounds) can be incorporated into various types of ophthalmic formulations for delivery to the eye. These compounds may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form an aqueous, sterile ophthalmic suspension or solution. Ophthalmic solution

formulations may be prepared by dissolving the compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound. The ophthalmic solution may also contain a thickener such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac. In order to prepare sterile ophthalmic ointment formulations, the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-940, or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.

The compounds are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 6.0 to 8.0. The H_1 antagonists will normally be contained in these formulations in an amount 0.01% to 0.3% by weight, but preferably in an amount of 0.05% to 0.1% by weight. The safe steroids will normally be contained in those formulations in an amount 0.05% to 1.5% by weight, but preferably in an amount of 0.1% to 1.0% by weight. Thus, for topical presentation 1 to 2 drops of these formulations would be delivered to the surface of the eye up to 4 times per day according to the routine discretion of a skilled clinician.

The preferred compositions of the present invention includes 0.01% to 0.05% emedastine and 0.1% to 1.0% dexamethasone betaxolol or loteprednol.

The following example is illustrative of the composition of the present invention, but in no way limiting.

EXAMPLE


Ingredient	Weight %
Emedastine	0.05%
Dexamethasone beloxil	0.1%
Hydroxypropyl methylcellulose	0.5%
Dibasic sodium phosphate	0.2%
Disodium EDTA	0.01%
Sodium Chloride	0.75%
Polysorbate 80	0.01%
Benzalkonium chloride	0.01%
Sodium hydroxide, hydrochlorine acid	adjust to approx. 7.0
Water	q.s. 100%

We Claim:

1. A method of treating ocular conditions in mammals selected from the group consisting of VKC, GPC, and AKC which comprises administering a pharmaceutically effective amount of a composition comprising an H₁ antagonist and a safe steroid.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/29436

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 31/55 US CL : 514/218 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/218 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WEST		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,668,133 A (YANNI et al.) 16 September 1997, see the entire document.	1
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
A	document defining the general state of the art which is not considered to be of particular relevance	*T*
E	earlier document published on or after the international filing date	*X*
L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*
O	document referring to an oral disclosure, use, exhibition or other means	*Z*
P	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 28 DECEMBER 2000		Date of mailing of the international search report 08 FEB 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer  ZOHREH FAY Telephone No. (703) 308-1235